Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

384 results about "Methyltransferase" patented technology

Methyltransferases are a large group of enzymes that all methylate their substrates but can be split into several subclasses based on their structural features. The most common class of methyltransferases is class I, all of which contain a Rossman fold for binding S-Adenosyl methionine (SAM). Class II methyltransferases contain a SET domain, which are exemplified by SET domain histone methyltransferases, and class III methyltransferases, which are membrane associated. Methyltransferases can also be grouped as different types utilizing different substrates in methyl transfer reactions. These types include protein methyltransferases, DNA/RNA methyltransferases, natural product methyltransferases, and non-SAM dependent methyltransferases. SAM is the classical methyl donor for methyltrasferases, however, examples of other methyl donors are seen in nature. The general mechanism for methyl transfer is a SN2-like nucleophilic attack where the methionine sulfur serves as the nucleophile that transfers the methyl group to the enzyme substrate. SAM is converted to S-Adenosyl homocysteine (SAH) during this process. The breaking of the SAM-methyl bond and the formation of the substrate-methyl bond happen nearly simultaneously. These enzymatic reactions are found in many pathways and are implicated in genetic diseases, cancer, and metabolic diseases.

Spirocyclic MTA-cooperative prmts inhibitor

The present invention relates to compounds used as MTA-cooperative inhibitors of protein arginine N-methyl transferase 5 (PRMT5). In particular, the present invention relates to MTA-cooperative PRMT5 inhibitors, including their pharmaceutical compositions comprising the compounds and the methods of use thereof.
Owner:PHARMAENGINE INC

Recombinant escherichia coli with high yield of ergothioneine and method for preparing ergothioneine by using recombinant escherichia coli

The invention provides recombinant escherichia coli with high yield of ergothioneine and a method for preparing ergothioneine, the recombinant escherichia coli co-expresses ergothioneine anabolic enzymes Egt1 and Egt2, the methyltransferase structural domain of the Egt1 is derived from trichoderma reesei, mycobacterium smegmatis EgtD or rhizopus nigricans, and the methyltransferase structural domain of the Egt2 is derived from the trichoderma reesei, the mycobacterium smegmatis EgtD or the rhizopus nigricans. The histidine sulfoxide synthase structural domain is derived from trichoderma reesei, schizosaccharomyces pombe or rhizopus nigricans, and the Egt2 is derived from claviceps purpurea, neurospora crassa or aspergillus niger. After the recombinant escherichia coli obtained by screening is cultured for 68 hours in a 5L fermentation tank, the yield of ergothioneine can reach 5g / L or above; wherein after recombinant escherichia coli co-expressing Egt1 enzyme (the structural domain of methyltransferase is derived from mycobacterium smegmatis EgtD, and the structural domain of histidine sulfoxide synthase is derived from trichoderma reesei) and Egt2 enzyme (derived from neurospora crassa) are cultured in a 5L fermentation tank for 68 hours, the yield of ergothioneine can reach 8.7 g / L, and the production intensity reaches 127.9 mg / (L.h).
Owner:THE UNITED BIO-TECH (HENGQIN) CO LTD

PRMT5 inhibitor and application thereof

The invention provides a compound with methyltransferase inhibitory activity, and particularly provides a compound with PRMT5 inhibitory activity. The compound can be used for preparing a pharmaceutical composition for treating diseases related to PRMT5 activity. # imgabs0 #
Owner:SAILAN (HANGZHOU) BIOMEDICAL TECHNOLOGY CO LTD

Recombinant escherichia coli for de novo synthesis of anisic acid, method for producing anisic acid and application

ActiveCN119875975ABacteriaTransferasesEscherichia coliChorismate lyase
The invention provides recombinant escherichia coli for de novo synthesis of anisic acid. At least one of the following improvements is carried out on an escherichia coli starting strain: (1) overexpression of O-methyltransferase PSA-OMT1 from Pleuromyces sapidus, (2) overexpression of O-methyltransferase PSA-OMT1 from Pleuromyces sapidus, and (3) overexpression of O-methyltransferase PSA-OMT1 from Pleuromyces sapidus; the method comprises the following steps: carrying out overexpression on chorismate lyase UbiC derived from E.coli MG1655 or Providencia rustiana, and carrying out the overexpression on the chorismate lyase UbiC derived from E.coli MG1655 or Providencia rustiana; (2) carrying out overexpression on a 3-deoxy-D-arabic-heptanone acid 7-phosphate (DAHP) synthase feedback inhibition mutant AroGD146N derived from E.coli MG1655 on the basis of the step (1); and (3) overexpressing synthase PpsA derived from phosphoenolpyruvate (PEP) on the basis of the step (2), and knocking out a pykF gene for coding pyruvate kinase I. Therefore, in the fermentation process of the recombinant escherichia coli, the accumulation of the anisic acid in the fermentation liquor can be realized, the maximum anisic acid shake flask yield of the recombinant escherichia coli can reach 284.9 mg / L, and a foundation is laid for the subsequent construction of high-yield anisic acid engineering bacteria.
Owner:XIAN GREEN SPRING TECHNOLOGY CO LTD +1

Biosynthesis inhibitor of migratory locust aggregation pheromone 4-vinyl anisole and application thereof

PendingCN120505290ABiocideOrganic chemistryMigratory locustMethyltransferase
The invention provides a biosynthesis inhibitor of migratory locust aggregation pheromone 4-vinyl anisole and application of the biosynthesis inhibitor. The biosynthesis inhibitor of migratory locust aggregation pheromone 4-vinylanisole reduces the activity of 4-vinylphenol methyltransferase, and the 4-vinylphenol methyltransferase contains an amino acid sequence selected from the following sequences: (a) a sequence as shown in any one of SEQ ID No.1 and SEQ ID No.3; and (b) a sequence which is obtained by deleting, inserting and / or substituting one or more amino acid residues in the sequence shown in any one of SEQ ID No.1 and SEQ ID No.3 and has the activity of catalyzing generation of migratory locust aggregation pheromone 4-vinyl anisole. The inhibitor can be applied to biological prevention and control of migratory locusts, can keep locusts in a harmless scattered state instead of killing the locusts, provides a new method for biological prevention and control of migratory locusts, and has a wide application prospect.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI +1

Biosynthesis method for de novo synthesis of glabridin and strain

PendingCN120485303AFungiBacteriaCyclaseCytochrome P450 reductase
The invention relates to the field of biological engineering and technology, in particular to an enzyme for synthesizing glabridin, a biological synthesis method of glabridin and a bacterial strain. The invention discloses a series of glabridin synthesizing enzymes (phenylalanine ammonialyase, cinnamic acid-4-hydrogenase, tyrosine ammonialyase, p-coumaric acid coenzyme A ligase, chalcone synthase, chalcone reductase, chalcone isomerase, isoflavone synthase, 2-hydroxyisoflavone dehydratase, 4 '-oxymethyltransferase, 4'-hydroxymethyltransferase and 4 '-hydroxymethyltransferase) derived from glycyrrhiza glabra for the first time. ) can be used in the preparation of a compound (e.g., isoflavone 2 '-hydrogenase, isoflavone reductase, Vissisoketoreductase, isoprenyltransferase, pterocarpin reductase, oxidative cyclase, demethylase, cytochrome P450 reductase, and the like). The de novo synthesis of the glabridin in a microbial cell factory is realized for the first time, and the application prospect of the glabridin biological manufacturing industry is greatly promoted.
Owner:TSINGHUA UNIVERSITY

Genetically engineered bacterium and method for producing icaritin through whole-cell catalysis

PendingCN119530121ABacteriaTransferasesEscherichia coliCholine kinase
The invention relates to the technical field of bioengineering, and discloses a genetically engineered bacterium and a method for producing icaritin through whole-cell catalysis. By constructing double plasmids, choline kinase, isopentenyl phosphokinase, flavonoid 3-hydroxylase, flavonol synthase, isopentenyl transferase and oxymethyltransferase are simultaneously overexpressed in escherichia coli, so that a genetically engineered bacterium is constructed, and the engineering bacterium is used as a whole-cell catalyst to prepare a whole-cell engineering bacterium. The naringenin and the 3-methyl-2-butene-1-ol are used as substrates to be converted into the icaritin in a whole-cell catalysis mode, only one-step reaction is needed, the method is simple, rapid and high in efficiency, other chemical substances do not need to be additionally added in the conversion process, the cost is reduced, pollution to the environment is relieved, and the method is suitable for industrial production. And the biological production from low-price naringenin to high-added-value icaritin is realized.
Owner:HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD

Methyltransferase mutant, recombinant vector, recombinant bacterium and application of methyltransferase mutant in production of pterostilbene

The invention discloses a methyltransferase mutant, a recombinant vector, a recombinant bacterium and application of the methyltransferase mutant in production of pterostilbene, and relates to the technical field of bioengineering. According to the methyltransferase mutant provided by the invention, resveratrol generates pterostilbene under the catalytic action of methyltransferase, and compared with the unmutated methyltransferase, the mutated methyltransferase has the advantages that the affinity of enzyme and a substrate is improved, and the resveratrol is promoted to be converted into pterostilbene. The coding gene of the methyltransferase mutant is transferred into a chassis cell or a chassis strain and is fermented, so that the yield of the pterostilbene can be greatly increased, the efficient synthesis of the plant-derived antioxidant pterostilbene in the microbial chassis cell is realized, and the ever-increasing market demand of the pterostilbene can be met.
Owner:GUANGDONG TECHNION ISRAEL INST OF TECH

TRMT61A and application of TRMT61A inhibitor tetramethylthiuram disulfide in tumor immunotherapy

The invention provides application of TRMT61A and its inhibitor tetramethylthiuram disulfide in tumor immunotherapy, and relates to the technical field of biological medicine, clinical research proves that RNA m1A methyltransferase TRMT61A is highly expressed in tumor tissues and is related to poor prognosis of tumor patients, and can be used as one of tumor therapy targets. Meanwhile, high expression of the TRMT61A is related to poor prognosis of a tumor patient receiving anti-PD-1 immunotherapy, and after anti-PD-1 antibody immunotherapy is carried out on the patient with low TRMT61A expression level in the tumor of the patient, pathological complete relief is easier. Tetramethylthiuram disulfide inhibits TRMT61A, inhibits m1A modification regulation of TRMT61A on PD-L1 mRNA, increases PD-L1 protein expression, and is combined with a PD-1 antibody drug to significantly enhance the immunotherapy effect of the anti-PD-1 immune checkpoint drug in treating malignant tumors.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY (GUANGZHOU SEVERE MATERNAL TREATMENT CENTER GUANGZHOU ROUJI HOSPITAL)

Protein with dihydrofolate reductase activity and application thereof

PendingCN120536397ABacteriaTransferasesDihydrofolic acidTetrahydrofolic acid
The invention provides a protein with dihydrofolate reductase activity and application thereof. The protein provided by the invention is a mutant of dihydrofolate reductase based on a Streptococcus thermophilus source, and the amino acid sequence of the protein is as shown in SEQ ID NO: 1. The protein provided by the invention can catalyze folic acid to be converted into L-tetrahydrofolic acid. Based on the characteristic, the glucose dehydrogenase and the tetrahydrofolate methyltransferase are combined to realize synthesis of the L-5-methyltetrahydrofolate, so that the problems of low yield and environmental pollution of a chemical method for producing the L-5-methyltetrahydrofolate and complex reaction and high substrate cost of a biological method are solved, the production cost of the L-5-methyltetrahydrofolate is reduced, and the yield of the L-5-methyltetrahydrofolate is improved. The synthesis efficiency and the synthesis quality of the L-5-methyltetrahydrofolic acid are improved, and the method has a relatively good industrialization prospect.
Owner:EFFEPHARM (SHANGHAI) CO LTD

PRMT5 inhibitor and application thereof

The invention provides a compound with methyltransferase inhibitory activity, and particularly provides a compound with PRMT5 inhibitory activity, and the compound can be used for preparing a pharmaceutical composition for treating diseases related to PRMT5 activity. I) # imgabs0 #
Owner:SAILAN (HANGZHOU) BIOMEDICAL TECHNOLOGY CO LTD

Enzymes for synthesis of glabridin

The invention relates to the field of biological engineering and technology, in particular to an enzyme for synthesizing glabridin, a biological synthesis method of glabridin and an engineering-modified biological host. The invention discloses a series of glabridin synthesizing enzymes (4 '-O-methyltransferase, isoflavone 2'-hydrogenase, isoflavone reductase, Vissisoketoreductase, isoprenyltransferase, pterocarpin reductase, oxidative cyclase and demethylase) from glycyrrhiza glabra for the first time, and the glabridin synthesizing enzymes have corresponding activities in various biological hosts. The heterologous biosynthesis of the glabridin is realized for the first time, and the yield of the glabridin can reach 60% or above.
Owner:TSINGHUA UNIVERSITY

Application of MY-1B in preparation of medicine for improving ovarian aging

The invention discloses application of MY-1B in preparation of medicines for improving ovarian aging, belongs to the technical field of biological medicines, and aims to solve the problems of how to effectively delay ovarian aging and improve ovarian functions. Experiments prove that the mRNA m5C modification level of ovarian granular cells in the ovarian aging process is increased, and the expression level of methylated transferase Nsun2 is increased. Ovarian aging caused by mRNA m5C modification level increase can be improved by supplementing the MY-1B, which is embodied in that the MY-1B can reduce the mRNA m5C modification level of aging nest granular cells; the MY-1B can be used for effectively correcting the orbital cycle disorder of the aged ovary and delaying the decline of the ovarian function; the MY-1B plays an important role in reducing the apoptosis level of granulosa cells in senescent ovaries; the MY-1B can improve the storage capacity of ovaries and enhance the quality of oocytes, so that the fertilization rate and the embryonic development potential of the oocytes are improved.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI

Modified o-methyltransferases useful for production of o-methylated phenolic natural products

Disclosed are modified Type 1 O-methyltransferases (OMTs) and methods of using such modified OMTs. In some forms of the modified OMTs, the amino acid corresponding to Phe337 of Sorghum bicolor stilbene OMT (SbSOMT) is substituted with a polar amino acid. In some forms of the modified OMTs, the amino acid corresponding to Asn323 of Sorghum bicolor caffeic acid OMT (SbCOMT) is substituted with a hydrophobic amino acid. In some forms of the modified OMTs, the amino acid corresponding to Ile144 of SbSOMT is substituted with a polar amino acid. In some forms of the modified OMTs, the amino acid corresponding to Asn128 of SbCOMT is substituted with a hydrophobic amino acid.
Owner:THE UNIVERSITY OF HONG KONG

Tetrahydrofolate methyltransferase mutant, coding gene and application of tetrahydrofolate methyltransferase mutant

The invention belongs to the field of gene engineering and enzyme engineering, and particularly relates to a tetrahydrofolate methyltransferase mutant, a coding gene and application of the tetrahydrofolate methyltransferase mutant. The invention provides a tetrahydrofolate methyltransferase RcoDmdA mutant. The amino acid sequence of the mutant is as shown in one of SEQ ID NO.3 to SEQ ID NO.3. The invention also provides a preparation method of the tetrahydrofolate methyltransferase RcoDmdA mutant. The RcoDmdA mutant provided by the invention has higher catalytic activity, the feeding amount of a substrate THF is remarkably increased to 15-20g / L, the yield of a product L-5-MTHF is increased to 15-17g / L, the substrate conversion rate is high, and the tetrahydrofolate methyltransferase mutant and the coding gene provided by the invention have important industrial application values.
Owner:ZHEJIANG SHENGDA BIO PHARM +2

Biosynthesis method for improving yeast terpenoids

The invention belongs to but not limited to the technical field of gene engineering, and discloses a method for improving the biosynthesis of yeast terpenoids and application of the method, and the method for improving the biosynthesis of the yeast terpenoids based on m7G methyltransferase complex genes TRM8-TRM82 comprises the following steps: overexpressing a TRM8 gene and a TRM82 gene; in a saccharomyces cerevisiae engineering strain genome for producing terpenoids, a promoter of a yeast endogenous TRM8 gene is replaced by a constitutive promoter PGK1p, and a promoter of a yeast endogenous TRM82 gene is replaced by a constitutive promoter TEF1p, so that the production efficiency of the saccharomyces cerevisiae terpenoids can be improved. The invention constructs a new wine brewing yeast engineering bacterium for producing the terpenoid lupeol as a representative compound, and the yield of the lupeol can be effectively improved. The new metabolic engineering method for improving the biosynthesis of the yeast terpenoids based on the TRM8-TRM82 has a remarkable effect.
Owner:BINZHOU MEDICAL COLLEGE

Protein arginine methyltransferase-5 inhibitor and pharmaceutical use thereof

PCT designated stage expiredWO2025039979A1Organic active ingredientsOrganic chemistryDiseaseMedicine
The present invention relates to a protein arginine methyltransferase-5 (PRMT5) inhibitor and a pharmaceutical use thereof. Specifically, the present invention relates to a compound represented by general formula (I), a preparation method for the compound, a pharmaceutical composition comprising the compound, and a use of the compound as a PRMT5 inhibitor for treating diseases related to PRMT5 activity. The definitions of the groups in general formula (I) are the same as those in the description.
Owner:JIANGSU YAHONG MEDITECH CO LTD +1

METTL3 inhibitory compounds

The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z5 (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity 10 is implicated.
Owner:STORM THERAPEUTICS LIMITED

Amide substituted tricyclic guanidino compounds as PRMT5 inhibitors

Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The provided compounds are useful Protein arginine N-methyltransferase 5 (PRMT5) inhibitors. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of making such compounds. Additional utilities and advantages are described herein.
Owner:IDEAYA BIOSCIENCES INC

Triheterocyclic guanidino compounds as PRMT5 inhibitors

Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The provided compounds are useful Protein arginine N-methyltransferase 5 (PRMT5) inhibitors. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of making such compounds. Additional utilities and advantages are described herein.
Owner:IDEAYA BIOSCIENCES INC

Compound for inhibiting PRMT5 and pharmaceutical composition thereof

The invention provides a compound with methyltransferase inhibitory activity, and particularly provides a compound with PRMT5 inhibitory activity as shown in a formula I which is described in the specification. The compound can be used for preparing a pharmaceutical composition for treating diseases related to PRMT5 activity. # imgabs0 # I
Owner:SAILAN (HANGZHOU) BIOMEDICAL TECHNOLOGY CO LTD

Synthesis of 1n-methylpseudouridine and 1n-methylpseudouridine phosphates

A method of synthesising a 1N-alkyl derivative of pseudouridine comprises contacting a substrate with a methyltransferase in the presence of a cofactor to produce the 1N-alkyl derivative of pseudouridine. The substrate has a structure of: Formula (I). The 1N-methyl derivative of pseudouridine has a structure of: Formula (II). R1 is a hydroxyl group, a monophosphate group, a diphosphate group, or a triphosphate group. R2 is H or a hydroxyl group. R3 is a methyl group or an ethyl group. The cofactor is a source of a methyl group or an ethyl group. The methyltransferase is configured to transfer the methyl group or ethyl group from the cofactor to the substrate. Enzymatic synthesis of 1N-methyl derivatives of pseudouridine may be more efficient and produce less waste than chemical syntheses. Also provided are methyltransferases and buffers useful in the method; and polynucleotides, expression vectors, and microorganisms useful for producing the methyltransferases.
Owner:UAB BIOMATTER DESIGNS

Caffeic acid-O-methyltransferase 2 function-acquired mutant, recombinant expression vector and application thereof

The invention discloses a caffeic acid-O-methyltransferase 2 function acquired mutant, a recombinant expression vector and application thereof, and belongs to the technical field of crop biological breeding. It is found for the first time that after the 344 amino acid of tomato caffeic acid-O-methyltransferase 2 is changed into tryptophan (W) from cysteine (C), the melatonin content of tomatoes can be increased, the tomatoes can be endowed with broad-spectrum resistance to abiotic and biological stress, and the tomato caffeic acid-O-methyltransferase 2 can serve as a key target for tomato resistance breeding.
Owner:SHANDONG AGRICULTURAL UNIVERSITY

PRMT5 inhibitor and application thereof

The invention provides a compound with methyltransferase inhibitory activity, and particularly provides a compound with PRMT5 inhibitory activity as shown in a formula (I). The compound can be used for preparing a pharmaceutical composition for treating diseases related to PRMT5 activity. # imgabs0 #
Owner:SAILAN (HANGZHOU) BIOMEDICAL TECHNOLOGY CO LTD

Amide substituted triheterocyclic guanidino compounds as PRMT5 inhibitors

Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The provided compounds are useful Protein arginine N-methyltransferase 5 (PRMT5) inhibitors. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of making such compounds. Additional utilities and advantages are described herein.
Owner:IDEAYA BIOSCIENCES INC

Profiling method for determining epigenetic modifications

PCT designated stage expiredWO2025104430A1Microbiological testing/measurementNucleotideBiochemistry
A method for determining the modification status of nucleotide residues in a polynucleotide sample is disclosed. The method involves using a methyltransferase to apply a tag to unmodified nucleotide residues in the sample.
Owner:TAGOMICS LTD

Application of MY-1B in the preparation of drugs for improving ovarian senescence

The present invention discloses the application of MY-1B in the preparation of drugs for improving ovarian senescence, belonging to the technical field of biomedicine, aiming to solve the problem of how to effectively delay ovarian senescence and improve ovarian function. Experiments have proved that during ovarian senescence, the mRNA m<supgt;5< / supgt;C modification level and the expression level of methyltransferase in ovarian granulosa cells increase. Supplementation with MY-1B can improve the condition caused by mRNA m Nsun2 expression.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI

Use of snip1 as a target in the preparation or screening of antitumor drugs

ActiveCN116942816BCompound screeningApoptosis detectionMethyltransferaseNon-histone protein
The application belongs to the technical field of biotechnology and gene therapy, and particularly relates to application of SNIP1 protein as a target in preparation or screening of an antitumor drug. The application finds that the SNIP1 protein is a non-histone substrate of lysine methyltransferase KMT5A, which promotes breast cancer cell growth, invasion and lung metastasis through KMT5A-mediated K301 monomethylation; therefore, the SNIP1 protein can be used as a target for screening of an antitumor drug, and a drug obtained by screening and inhibiting methylation of the K301 site of the SNIP1 protein can be used for antitumor; and the application provides a polypeptide specifically combined with the K301 site of the SNIP1 protein, the polypeptide is combined with the K301 site of the SNIP1 protein, inhibits methylation of the SNIP1 protein, and finally can inhibit tumor growth, proliferation, invasion and metastasis, and can be used as a new targeted antitumor drug.
Owner:SUZHOU QINGRUI BIOTECHNOLOGY CO LTD

Tricyclic amidino compounds as PRMT5 inhibitors

Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The provided compounds are useful Protein arginine N-methyltransferase 5 (PRMT5) inhibitors. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of making such compounds. Additional utilities and advantages are described herein.
Owner:IDEAYA BIOSCIENCES INC

Class of PRMT5 inhibitors and use thereof

Provided is a class of compounds with methyltransferase inhibitory activity. Specifically, provided is a class of compounds with PRMT5 inhibitory activity. The compounds can be used for preparing a pharmaceutical composition for treating PRMT5 activity-related diseases.
Owner:CYTOSINLAB THERAPEUTICS CO LTD